Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin

Pantopoulou, Alkistis; Giamarellos‐Bourboulis, Evangelos J.; Raftogannis, Maria; Τσαγανός, Θωμάς; Dontas, Ismene; Koutoukas, Pantelis; Baziaka, Fotini; Giamarellou, Helen; Perrea, Despina

doi:10.1016/j.ijantimicag.2006.09.009

Cited by 70 publications

(61 citation statements)

References 14 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, exposure to polymyxin B or colistin alone routinely results in regrowth. Many A few studies have looked at the in vivo efficacies of polymyxins against multidrug-resistant P. aeruginosa and A. baumannii strains in animal models of infection (28,29,124,125,137,149). In general, there was a tendency for colistin to reduce mortality in sepsis models using single-dose therapy (29,137).…”

Section: Bactericidal Activity and Synergy Studiesmentioning

confidence: 99%

“…Many A few studies have looked at the in vivo efficacies of polymyxins against multidrug-resistant P. aeruginosa and A. baumannii strains in animal models of infection (28,29,124,125,137,149). In general, there was a tendency for colistin to reduce mortality in sepsis models using single-dose therapy (29,137). However, colistin monotherapy appeared to be less effective against A. baumannii in pneumonia and endocarditis models (124,125,149).…”

Section: Bactericidal Activity and Synergy Studiesmentioning

confidence: 99%

“…However, colistin monotherapy appeared to be less effective against A. baumannii in pneumonia and endocarditis models (124,125,149). The addition of rifampin or imipenem enhanced bacterial clearance in several studies (28,29,137). Definitive conclusions cannot be drawn from the studies because of the varied experimental models, varied drug preparation and dosage, small number of strains tested, and brief duration of therapy used.…”

Section: Bactericidal Activity and Synergy Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Polymyxins Revisited

et al. 2008

View full text Add to dashboard Cite

SUMMARY The global emergence of multidrug-resistant gram-negative bacilli has spurred a renewed interest in polymyxins. Once discarded due to concerns regarding nephrotoxicity and neurotoxicity, polymyxins now hold an important role in the antibiotic armamentarium. However, more reliable information is needed to determine the optimal dosing of these agents. Also, unanswered questions regarding in vitro testing remain, including questions regarding the reliability of automated systems and the establishment of appropriate breakpoints for defining susceptibility. Most contemporary clinical studies examining the use of these agents have involved patients with infections due to multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii strains. It has been reassuring that polymyxin therapy for resistant bacteria has resulted in clinical responses and toxicity rates similar to those for carbapenem therapy for susceptible isolates. While most surveillance studies demonstrated high rates of susceptibility, several reports noted the emergence of polymyxin-resistant nosocomial pathogens. Polymyxins have assumed an important antibiotic niche for therapy for hospital-acquired infections; further studies defining the optimal use of these agents will likely extend the duration of their clinical usefulness.

show abstract

Section: Bactericidal Activity and Synergy Studiesmentioning

confidence: 99%

Section: Bactericidal Activity and Synergy Studiesmentioning

confidence: 99%

Section: Bactericidal Activity and Synergy Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Polymyxins Revisited

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Synergy against MDR or XDR A. baumannii was shown in both in vitro (62)(63)(64) and experimental studies (65,66) when colistin was combined with rifampicin. By altering membrane permeability, colistin may facilitate rifampicin entry within the bacterial cell and therefore enhance its killing activity (67,68).…”

Section: Colistin-rifampicinmentioning

confidence: 97%

Intravenous polymyxins: Revival with puzzle

Fei

et al. 2017

BST

View full text Add to dashboard Cite

“…Polymyxins combined with tigecycline, rifampicin or meropenem may be bactericidal in XDR Acinetobacter strains (Wareham & Bean, 2006;Lim et al, 2011). The combination of rifampicin with colistin has been advocated by some authors after consistent in vitro demonstrations (Timurkaynak et al, 2006;Pantopoulou et al, 2007). The synergism of rifampicin with colistin seems to be evident, although it may only occur late (w36 h) in animal models (Hogg et al, 1998;Song et al, 2009).…”

Section: In Vitromentioning

confidence: 99%